

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Triple-negative breast cancer: recent treatment... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1342/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1342" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Triple-negative breast cancer: recent treatment advances" />
    
            <meta name="og:title" content="F1000Research Article: Triple-negative breast cancer: recent treatment advances.">
            <meta name="og:description" content="Read the latest article version by Alice R T Bergin, Sherene Loi, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="20701">
            <meta name="article-id" content="18888">
            <meta name="dc.title" content="Triple-negative breast cancer: recent treatment advances">
            <meta name="dc.description" content="Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to affect younger women, metastasise early despite optimal adjuvant treatment and carry a poor prognosis. Neoadjuvant therapy has focused on combinations of systemic agents to optimise pathological complete response. Treatment algorithms now guide the management of patients with or without residual disease, but metastatic TNBC continues to harbour a poor prognosis. Innovative, multi-drug combination systemic therapies in the neoadjuvant and adjuvant settings have led to significant improvements in outcomes, particularly over the past decade. Recently published advances in the treatment of metastatic TNBC have shown impressive results with poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy agents. Immunotherapy agents in combination with traditional systemic chemotherapy have been shown to alter the natural history of this devastating condition, particularly in patients whose tumours are positive for programmed cell death ligand 1 (PD-L1).">
            <meta name="dc.subject" content="Triple negative breast cancer, Immunotherapy">
            <meta name="dc.creator" content="Bergin, Alice R T">
            <meta name="dc.creator" content="Loi, Sherene">
            <meta name="dc.date" content="2019/08/02">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.18888.1">
            <meta name="dc.source" content="F1000Research 2019 8:1342">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Triple negative breast cancer">
            <meta name="prism.keyword" content="Immunotherapy">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/08/02">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1342">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.18888.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1342">
            <meta name="citation_title" content="Triple-negative breast cancer: recent treatment advances">
            <meta name="citation_abstract" content="Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to affect younger women, metastasise early despite optimal adjuvant treatment and carry a poor prognosis. Neoadjuvant therapy has focused on combinations of systemic agents to optimise pathological complete response. Treatment algorithms now guide the management of patients with or without residual disease, but metastatic TNBC continues to harbour a poor prognosis. Innovative, multi-drug combination systemic therapies in the neoadjuvant and adjuvant settings have led to significant improvements in outcomes, particularly over the past decade. Recently published advances in the treatment of metastatic TNBC have shown impressive results with poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy agents. Immunotherapy agents in combination with traditional systemic chemotherapy have been shown to alter the natural history of this devastating condition, particularly in patients whose tumours are positive for programmed cell death ligand 1 (PD-L1).">
            <meta name="citation_description" content="Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to affect younger women, metastasise early despite optimal adjuvant treatment and carry a poor prognosis. Neoadjuvant therapy has focused on combinations of systemic agents to optimise pathological complete response. Treatment algorithms now guide the management of patients with or without residual disease, but metastatic TNBC continues to harbour a poor prognosis. Innovative, multi-drug combination systemic therapies in the neoadjuvant and adjuvant settings have led to significant improvements in outcomes, particularly over the past decade. Recently published advances in the treatment of metastatic TNBC have shown impressive results with poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy agents. Immunotherapy agents in combination with traditional systemic chemotherapy have been shown to alter the natural history of this devastating condition, particularly in patients whose tumours are positive for programmed cell death ligand 1 (PD-L1).">
            <meta name="citation_keywords" content="Triple negative breast cancer, Immunotherapy">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Alice R T Bergin">
            <meta name="citation_author_institution" content="Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia">
            <meta name="citation_author" content="Sherene Loi">
            <meta name="citation_author_institution" content="Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia">
            <meta name="citation_author_institution" content="Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia">
            <meta name="citation_publication_date" content="2019/08/02">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1342">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.18888.1">
            <meta name="citation_firstpage" content="1342">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1342/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1342.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=20701 /> <input type=hidden id=articleId name=articleId value=18888 /> <input type=hidden id=xmlUrl value="/articles/8-1342/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1342-v1.xml"> <input type=hidden id=article_uuid value=12dc649f-058a-4275-9036-eded4cbc270a /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Triple-negative breast cancer: recent treatment advances"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.18888.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.18888.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1342"
  },
  "headline": "Triple-negative breast cancer: recent treatment advances",
  "datePublished": "2019-08-02T15:54:13",
  "dateModified": "2019-08-02T15:54:13",
  "author": [
    {
      "@type": "Person",
      "name": "Alice R T Bergin"
    },    {
      "@type": "Person",
      "name": "Sherene Loi"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to affect younger women, metastasise early despite optimal adjuvant treatment and carry a poor prognosis. Neoadjuvant therapy has focused on combinations of systemic agents to optimise pathological complete response. Treatment algorithms now guide the management of patients with or without residual disease, but metastatic TNBC continues to harbour a poor prognosis. Innovative, multi-drug combination systemic therapies in the neoadjuvant and adjuvant settings have led to significant improvements in outcomes, particularly over the past decade. Recently published advances in the treatment of metastatic TNBC have shown impressive results with poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy agents. Immunotherapy agents in combination with traditional systemic chemotherapy have been shown to alter the natural history of this devastating condition, particularly in patients whose tumours are positive for programmed cell death ligand 1 (PD-L1)."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1342",
            "name": "Triple-negative breast cancer: recent treatment advances"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Triple-negative breast cancer: recent treatment advances </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=20701 data-id=18888 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18888.1" data-recommended="" data-doi="10.12688/f1000research.18888.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1342/v1/pdf?article_uuid=12dc649f-058a-4275-9036-eded4cbc270a" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-18888-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-18888-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-18888-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Bergin ART and Loi S. Triple-negative breast cancer: recent treatment advances [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1342 (<a class=new-orange href="https://doi.org/10.12688/f1000research.18888.1" target=_blank>https://doi.org/10.12688/f1000research.18888.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-18888-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=18888 id=track-article-signin-18888 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18888?target=/articles/8-1342">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20701 /> <input name=articleId type=hidden value=18888 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Triple-negative breast cancer: recent treatment advances</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Alice R T Bergin<a href="https://orcid.org/0000-0002-2150-879X" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2150-879X</div><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:sherene.loi@petermac.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Sherene Loi</span></a><a href="https://orcid.org/0000-0001-6137-9171" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-6137-9171</div><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Alice R T Bergin<a href="http://orcid.org/0000-0002-2150-879X" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2150-879X</div><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:sherene.loi@petermac.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Sherene Loi</span></a><a href="http://orcid.org/0000-0001-6137-9171" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-6137-9171</div><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 02 Aug 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.18888.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia<br/> <sup>2</sup> Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia<br/> <p> <div class=margin-bottom> Alice R T Bergin <br/> <span>Roles: </span> Investigation, Methodology, Writing – Original Draft Preparation </div> <div class=margin-bottom> Sherene Loi <br/> <span>Roles: </span> Supervision, Validation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=50851-52025></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=54312-52030></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to affect younger women, metastasise early despite optimal adjuvant treatment and carry a poor prognosis. Neoadjuvant therapy has focused on combinations of systemic agents to optimise pathological complete response. Treatment algorithms now guide the management of patients with or without residual disease, but metastatic TNBC continues to harbour a poor prognosis. Innovative, multi-drug combination systemic therapies in the neoadjuvant and adjuvant settings have led to significant improvements in outcomes, particularly over the past decade. Recently published advances in the treatment of metastatic TNBC have shown impressive results with poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy agents. Immunotherapy agents in combination with traditional systemic chemotherapy have been shown to alter the natural history of this devastating condition, particularly in patients whose tumours are positive for programmed cell death ligand 1 (PD-L1). </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Triple negative breast cancer, Immunotherapy </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Sherene Loi (<a href="mailto:sherene.loi@petermac.org">sherene.loi@petermac.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Sherene Loi </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> AB has received travel funding from Pfizer. SL receives research funding to her institution from Novartis, Bristol-Myers Squibb, Merck, Roche-Genentech, Puma Biotechnology and Pfizer. She has acted as consultant (not compensated) to Seattle Genetics, Pfizer, Novartis, Bristol-Myers Squibb, Merck and Roche-Genentech. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Bergin ART and Loi S. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Bergin ART and Loi S. Triple-negative breast cancer: recent treatment advances [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1342 (<a href="https://doi.org/10.12688/f1000research.18888.1" target=_blank>https://doi.org/10.12688/f1000research.18888.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 02 Aug 2019, <b>8</b>(F1000 Faculty Rev):1342 (<a href="https://doi.org/10.12688/f1000research.18888.1" target=_blank>https://doi.org/10.12688/f1000research.18888.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 02 Aug 2019, <b>8</b>(F1000 Faculty Rev):1342 (<a href="https://doi.org/10.12688/f1000research.18888.1" target=_blank>https://doi.org/10.12688/f1000research.18888.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d8627e158>Introduction</h2><p class="" id=d8627e161>Triple-negative breast cancer (TNBC) is a molecularly diverse<sup><a href="#ref-1">1</a></sup> breast cancer subtype currently defined by what it lacks. With hormone receptor immunohistochemistry (IHC) stains of less than 1% for oestrogen and progesterone<sup><a href="#ref-2">2</a></sup> and the absence of HER2 protein overexpression or <i>HER2</i> gene amplification (or both)<sup><a href="#ref-3">3</a></sup>, TNBC accounts for 12 to 17% of all breast cancers, typically affects younger women and typically carries a poor prognosis<sup><a href="#ref-4">4</a></sup>. Metastatic progression in this phenotype is typically marked by early relapse and a predominance of hepatic, pulmonary and central nervous system metastasis<sup><a href="#ref-5">5</a></sup>.</p><p class="" id=d8627e188>Despite, or perhaps because of, its aggressive nature and the lack of current targeted treatments, significant clinical and laboratory research is providing nuanced treatment options. Historically, chemotherapy has been the only viable systemic treatment option for early and advanced disease. However, recently published clinical trials have shown that immunotherapy has an important role in the treatment paradigm of this devastating condition.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d8627e194>Neoadjuvant chemotherapy for early-stage disease and optimising rates of pathological complete response</h2><p class="" id=d8627e197>Although it is generally accepted that early-stage TNBC is chemotherapy-sensitive, the optimal treatment regimen remains undefined. Neoadjuvant chemotherapy is a standard of care for a locally advanced or inoperable TNBC. A major advantage of this approach is the ability to pre-emptively predict survival according to the presence or absence of a pathological complete response (pCR) at the time of surgery and tailor adjuvant therapy. Patients with TNBC, as opposed to those with the luminal subtypes, are more likely to achieve a pCR with neoadjuvant chemotherapy<sup><a href="#ref-6">6</a></sup>. Achieving pCR (defined as no invasive or <i>in situ</i> disease in the breast or lymph nodes) at the time of surgery is associated with a significant improvement in disease-free survival (DFS)<sup><a href="#ref-7">7</a>–<a href="#ref-9">9</a></sup>; as such, pCR is considered a surrogate outcome end point. However, it is unclear whether changes in pCR will ultimately equate to improvements in overall survival (OS) and thus the use of pCR as a robust trial end point is debated.</p><p class="" id=d8627e214>Clinicians often adopt an intensive approach with sequential anthracycline and taxane regimens and the evidence for this derives from retrospective, subgroup analyses of clinical trials reported before 2010 (<a href="#T1">Table 1</a>).</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Neoadjuvant breast cancer clinical trials pre-2010, including patients with triple-negative breast cancer and showing modest pathological complete response rates with combinations of chemotherapy.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d8627e231 class=n-a></a><thead><a name=d8627e233 class=n-a></a><tr><a name=d8627e235 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e237 class=n-a></a>Number of patients with<br class=br>triple-negative breast cancer</th><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e242 class=n-a></a>Trial arms<br class=br>(number of patients)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e247 class=n-a></a>Pathological complete<br class=br>response rate</th><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e252 class=n-a></a>Reference</th></tr></thead><tbody><a name=d8627e257 class=n-a></a><tr><a name=d8627e259 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e261 class=n-a></a>96</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e264 class=n-a></a>Intensified FAC (56)<br class=br>FEC (40)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e269 class=n-a></a>Intensified FAC: 47%<br class=br>FEC: 13% Combined:<br class=br>29%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e276 class=n-a></a><a href="#ref-10">10</a></td></tr><tr><a name=d8627e281 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e283 class=n-a></a>120</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e286 class=n-a></a>FAC or FEC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e289 class=n-a></a>17%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e292 class=n-a></a><a href="#ref-11">11</a></td></tr><tr><a name=d8627e297 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e299 class=n-a></a>22</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e302 class=n-a></a>T-FAC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e305 class=n-a></a>45%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e308 class=n-a></a><a href="#ref-19">19</a></td></tr><tr><a name=d8627e313 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e315 class=n-a></a>23</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e318 class=n-a></a>Anthracycline and taxane</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e321 class=n-a></a>39%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e324 class=n-a></a><a href="#ref-12">12</a></td></tr><tr><a name=d8627e329 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e331 class=n-a></a>34</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e334 class=n-a></a>AC ± taxane</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e337 class=n-a></a>27%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e340 class=n-a></a><a href="#ref-13">13</a></td></tr><tr><a name=d8627e346 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e348 class=n-a></a>47</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e351 class=n-a></a>D and A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e354 class=n-a></a>17%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e357 class=n-a></a><a href="#ref-14">14</a></td></tr><tr><a name=d8627e362 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e364 class=n-a></a>255</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e367 class=n-a></a>A: FAC or FEC or AC (70)<br class=br>B: T-FAC or T-FEC (125)<br class=br>C: Taxane only (17)<br class=br>D: Other (43)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e376 class=n-a></a>A: 20% B: 28% C: 12%<br class=br>D: 14%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e381 class=n-a></a><a href="#ref-6">6</a></td></tr><tr><a name=d8627e386 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e388 class=n-a></a>45</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e391 class=n-a></a>AC → T</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e394 class=n-a></a>34%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e397 class=n-a></a><a href="#ref-15">15</a></td></tr><tr><a name=d8627e402 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e404 class=n-a></a>21</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e407 class=n-a></a>Anthracycline and taxane</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e410 class=n-a></a>38%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e413 class=n-a></a><a href="#ref-16">16</a></td></tr><tr><a name=d8627e418 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e420 class=n-a></a>38</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e423 class=n-a></a>AC or AT Or T/cape</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e426 class=n-a></a>34%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e429 class=n-a></a><a href="#ref-17">17</a></td></tr><tr><a name=d8627e434 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e436 class=n-a></a>22</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e439 class=n-a></a>Cis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e442 class=n-a></a>23%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e445 class=n-a></a><a href="#ref-20">20</a></td></tr><tr><a name=d8627e451 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e453 class=n-a></a>12</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e456 class=n-a></a>Cp and T</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e459 class=n-a></a>67%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e462 class=n-a></a><a href="#ref-21">21</a></td></tr><tr><a name=d8627e467 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e469 class=n-a></a>30</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e472 class=n-a></a>E/Cis/F → T</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e475 class=n-a></a>40%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e478 class=n-a></a><a href="#ref-22">22</a></td></tr><tr><a name=d8627e483 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e485 class=n-a></a>125</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e488 class=n-a></a>Platinum and D ± AC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e491 class=n-a></a>34%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e494 class=n-a></a><a href="#ref-23">23</a></td></tr><tr><a name=d8627e499 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e501 class=n-a></a>10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e504 class=n-a></a>Cis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e507 class=n-a></a>90%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e510 class=n-a></a><a href="#ref-24">24</a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d8627e519 class=n-a></a><p id=d8627e521> A, doxorubicin; AC, doxorubicin and cyclophosphamide; Cape, capecitabine; Cis, cisplatin; Cp, carboplatin; D, docetaxel; E/Cis/F, epirubicin and cisplatin and 5-fluorouracil; FAC, 5-fluorouracil and doxorubicin and cyclophosphamide; FEC, 5-fluorouracil and epirubicin and cyclophosphamide; T, paclitaxel.</p></div></div></div><p class="" id=d8627e527>Anthracyclines alone had reported pCR rates of 14 to 47%<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>, whereas sequential anthracycline and taxane regimens had reported pCR rates of 17 to 39%<sup><a href="#ref-6">6</a>,<a href="#ref-12">12</a>–<a href="#ref-17">17</a></sup>. GeparTrio reported pCR rates up to 57% for TNBC managed with neoadjuvant anthracyclines, cyclophosphamide and taxanes<sup><a href="#ref-18">18</a></sup>. Since then, clinical trials have attempted to define which combination of systemic agents results in the highest rates of pCR (<a href="#T2">Table 2</a>).</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Neoadjuvant triple-negative breast cancer clinical trials post-2010 showing pathological complete response rates with combinations of chemotherapy, PARP inhibitors and novel agents.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d8627e566 class=n-a></a><thead><a name=d8627e568 class=n-a></a><tr><a name=d8627e570 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e572 class=n-a></a>Study<br class=br>Phase<br class=br>ClinicalTrials.gov Identifier</th><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e579 class=n-a></a>Number of<br class=br>patients</th><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e584 class=n-a></a>Trial arms</th><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e587 class=n-a></a>Pathological complete<br class=br>response</th></tr></thead><tbody><a name=d8627e594 class=n-a></a><tr><a name=d8627e596 class=n-a></a><td align=left colspan=4 rowspan=1 valign=top><a name=d8627e598 class=n-a></a><b>PARP inhibitors</b></td></tr><tr><a name=d8627e603 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e605 class=n-a></a>BrighTNess<sup><a href="#ref-25">25</a></sup><br class=br>Phase 3<br class=br>NCT02032277</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e615 class=n-a></a>A: 316 B: 160<br class=br>C: 158</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e620 class=n-a></a>A: Veliparib + Cp + T → AC<br class=br>B: Placebo and Cp and T → AC<br class=br>C: Placebo and T → AC.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e627 class=n-a></a>A: 53% B: 58% C: 31%</td></tr><tr><a name=d8627e631 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e633 class=n-a></a>Talazoparib<sup><a href="#ref-26">26</a></sup><br class=br>Phase 2<br class=br>NCT02282345</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e643 class=n-a></a>17</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e646 class=n-a></a>24 weeks Tala<br class=br>(no neoadjuvant chemotherapy)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e651 class=n-a></a>47%<sup><a href="#TFN1">a</a></sup></td></tr><tr><a name=d8627e658 class=n-a></a><td align=left colspan=4 rowspan=1 valign=top><a name=d8627e660 class=n-a></a><b>Anthracycline, taxane and platinum combinations</b></td></tr><tr><a name=d8627e665 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e667 class=n-a></a>GeparSepto GBG 69<sup><a href="#ref-27">27</a></sup><br class=br>Phase 3<br class=br>NCT01583426</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e677 class=n-a></a>276</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e680 class=n-a></a>Nab-pac → EC Pac → EC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e683 class=n-a></a>Nab-pac: 56% Pac: 37%</td></tr><tr><a name=d8627e688 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e690 class=n-a></a>ETNA<sup><a href="#ref-28">28</a></sup><br class=br>Phase 3<br class=br>NCT01822314</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e700 class=n-a></a>219</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e703 class=n-a></a>Nab-pac → AC or EC or FEC Pac → AC<br class=br>or EC or FEC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e708 class=n-a></a>Nab-pac: 41% Pac: 37% </td></tr><tr><a name=d8627e712 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e714 class=n-a></a>WSG-ADAPT-TN<sup><a href="#ref-29">29</a></sup><br class=br>Phase 2<br class=br>NCT01815242</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e724 class=n-a></a>336</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e727 class=n-a></a>Nab-pac and gem Nab-pac and Cp</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e730 class=n-a></a>Nab-pac and gem: 28.7%<br class=br>Nab-pac and Cp: 45.9%</td></tr><tr><a name=d8627e736 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e738 class=n-a></a>Phase 2<sup><a href="#ref-30">30</a></sup><br class=br>NCT01276769</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e746 class=n-a></a>91</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e749 class=n-a></a>T and Cp → surgery → anthracycline<br class=br>EP → surgery → taxane</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e754 class=n-a></a>T and Cp: 38.6% EP: 4%</td></tr><tr><a name=d8627e758 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e760 class=n-a></a>GEICAM/2006-03<sup><a href="#ref-31">31</a></sup><br class=br>NCT00432172</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e768 class=n-a></a>94</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e771 class=n-a></a>EC-D or EC-D and Cp </td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e774 class=n-a></a>EC-D: 30% EC-D &amp; Cp: 30%</td></tr><tr><a name=d8627e778 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e780 class=n-a></a>Cisplatin-1<sup><a href="#ref-32">32</a></sup><br class=br>NCT00148694</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e788 class=n-a></a>28</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e791 class=n-a></a>Neoadjuvant cis → surgery → adjuvant<br class=br>chemotherapy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e796 class=n-a></a>22%</td></tr><tr><a name=d8627e800 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e802 class=n-a></a>Phase 1<sup><a href="#ref-33">33</a></sup><br class=br>NCT01090128</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e810 class=n-a></a>10<br class=br>(TNBC cohort)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e815 class=n-a></a>Nab-pac AC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e818 class=n-a></a>100%</td></tr><tr><a name=d8627e823 class=n-a></a><td align=left colspan=4 rowspan=1 valign=top><a name=d8627e825 class=n-a></a><b>Chemotherapy backbone with or without novel agents</b></td></tr><tr><a name=d8627e830 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e832 class=n-a></a>PrECOG 0105<sup><a href="#ref-34">34</a></sup><br class=br>Phase 2<br class=br>NCT00813956</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e842 class=n-a></a>80</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e845 class=n-a></a>Gemcitabine, Cp, iniparib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e848 class=n-a></a>36%</td></tr><tr><a name=d8627e852 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e854 class=n-a></a>Cisplatin-2<br class=br>NCT00580333</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e859 class=n-a></a>51</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e862 class=n-a></a>Cis and Bev</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e865 class=n-a></a>16% </td></tr><tr><a name=d8627e869 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e871 class=n-a></a>CALGB 40603<sup><a href="#ref-35">35</a></sup><br class=br>Phase 2<br class=br>NCT00861705</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e881 class=n-a></a>454</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e884 class=n-a></a>T ± Cp ± bev → ddAC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e887 class=n-a></a>No Cp: 41% with Cp: 54%<br class=br>No bev: 52% Bev: 44%<br class=br>Cp and bev: 60% </td></tr><tr><a name=d8627e895 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e897 class=n-a></a>Phase 2<sup><a href="#ref-36">36</a></sup><br class=br>NCT00930930</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e905 class=n-a></a>145</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e908 class=n-a></a>Cis + T ± everolimus</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e911 class=n-a></a>Everolimus: 36%<br class=br>Placebo: 49% </td></tr><tr><a name=d8627e917 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e919 class=n-a></a>Phase 2<sup><a href="#ref-37">37</a></sup><br class=br>NCT00600249</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e927 class=n-a></a>35</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e930 class=n-a></a>Cetuximab and D</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e933 class=n-a></a>pCR: 24% </td></tr><tr><a name=d8627e938 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e940 class=n-a></a>GeparQuinto GBG 44<sup><a href="#ref-38">38</a></sup><br class=br>Phase 3<br class=br>NCT00567554</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e950 class=n-a></a>663</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e953 class=n-a></a>EC → D ± bev</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e956 class=n-a></a>With bev: 39.3% No bev:<br class=br>27.9%</td></tr><tr><a name=d8627e962 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e964 class=n-a></a>Phase 2<sup><a href="#ref-39">39</a></sup><br class=br>NCT00933517</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e972 class=n-a></a>47</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e975 class=n-a></a>Panitumumab and FEC-D</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e978 class=n-a></a>46.8% </td></tr><tr><a name=d8627e982 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e984 class=n-a></a>GeparSixto GBG 66<sup><a href="#ref-40">40</a></sup><br class=br>Phase 3<br class=br>NCT01426880</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e994 class=n-a></a>315 (TNBC<br class=br>cohort)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e999 class=n-a></a>T and Liposomal doxorubicin and<br class=br>Bev ± Cp</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1004 class=n-a></a>53.2% with Cp<br class=br>36.9% no Cp </td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d8627e1014 class=n-a></a><p id=TFN1> AC, doxorubicin and cyclophosphamide; Bev, bevacizumab; Cis, cisplatin; Cp, carboplatin; D, docetaxel; ddAC, dose dense doxorubicin and cyclophosphamide; EC, epirubicin and cyclophosphamide; EP, epirubicin and paclitaxel; FEC, 5-fluorouracil and epirubicin and cyclophosphamide; gem, gemcitabine; Nab-pac, nab-paclitaxel; pac, paclitaxel; PARP, poly (ADP-ribose) polymerase; T, paclitaxel; Tala, talazoparib; TNBC, triple-negative breast cancer. <sup>a</sup>Reported as residual cancer burden (RCB) and results represent RCB 0, equivalent to pathological complete response (pCR).</p></div></div></div><p class="" id=d8627e1025>Alkylating agents like carboplatin and cisplatin have provided additional improvements in rates of pCR. Given that a proportion of TNBC tumours have a functional alteration in breast cancer gene 1 (<i>BRCA1</i>), analysis of the role of inter-strand cross-linking agents is especially prudent. The coupling of platinum-induced DNA damage and deficiencies in BRCA-associated DNA repair<sup><a href="#ref-13">13</a></sup> has been exploited in phase 2 trials of platinum monotherapy and yielded promising pCR rates of 23 to 90%<sup><a href="#ref-20">20</a>,<a href="#ref-24">24</a>,<a href="#ref-32">32</a></sup>, and rates of pCR were higher amongst BRCA mutation carriers<sup><a href="#ref-24">24</a>,<a href="#ref-32">32</a></sup>. Although the randomised phase 2 GEICAM 2006-03<sup><a href="#ref-31">31</a></sup> did not lead to a significant improvement in pCR, GeparSixto<sup><a href="#ref-40">40</a></sup> and CALGB 40603<sup><a href="#ref-35">35</a></sup> reported higher rates of pCR with the addition of carboplatin. It is important to note that the addition of carboplatin in these trials led to a significant increase in toxicity and that, for CALGB 40603, the improved pCR rate translated into a modest 5% improvement in 3-year event-free survival, which was not statistically significant<sup><a href="#ref-35">35</a></sup>.</p><p class="" id=d8627e1069>In further attempts to manipulate homologous recombination deficiencies inherent to <i>BRCA1</i> and <i>BRCA2</i> germline mutant tumours, poly (ADP-ribose) polymerase (PARP) inhibitors have been added to the neoadjuvant cocktail. PARP inhibitors act by inducing synthetic lethality in BRCA-deficient cells whilst sparing cells with preserved BRCA function. The phase 3 BrighTNess clinical trial saw a pCR improvement that was attributable to carboplatin rather than the PARP inhibitor under investigation, veliparib<sup><a href="#ref-25">25</a></sup>. PrECOG 0105, a single-arm phase 2 clinical trial of gemcitabine, carboplatin and iniparib, yielded a promising pCR of 36%, and response rates were higher in those tumours with elevated mean homologous recombination deficiency-loss of heterozygosity (HRD-LOH) scores, a DNA-based measure of genomic instability<sup><a href="#ref-34">34</a>,<a href="#ref-41">41</a></sup>. Although iniparib is no longer considered a true PARP inhibitor<sup><a href="#ref-42">42</a>–<a href="#ref-44">44</a></sup>, these results are compelling. It is possible that the different PARP agents will have differing efficacy because of PARP trapping<sup><a href="#ref-45">45</a></sup>. Certainly, promising pCR rates were seen in patients with germline BRCA-mutated early-stage breast cancers with just talozparib alone<sup><a href="#ref-26">26</a></sup>.</p><p class="" id=d8627e1105>Novel agents like the monoclonal antibodies bevacizumab, panitumumab and cetuximab have been assessed with mixed results (<a href="#T2">Table 2</a>). The randomised phase 3 GeparQuinto reported that an improvement was seen in rates of pCR with the addition of bevacizumab, but the survival analysis did not show a significant difference<sup><a href="#ref-38">38</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d8627e1118>Managing residual disease following neoadjuvant chemotherapy</h2><p class="" id=d8627e1121>Although attaining pCR is the goal of neoadjuvant therapy, optimal management of those who do not meet this end point is critical as these patients have a relapse risk that is six to nine times higher than that of patients achieving pCR<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>.</p><p class="" id=d8627e1131>The CREATE-X clinical trial showed that six to eight cycles of adjuvant capecitabine (1250 mg/m<sup>2</sup> from days 1 to 14, every 21 days) improved DFS and OS in the TNBC cohort. DFS rates were 69.8% in the capecitabine arm and 56.1% in the control arm (hazard ratio [HR] 0.58 for recurrence, second cancer, or death; 95% confidence interval [CI] 0.39–0.87), and OS rates were 78.8% and 70.3% (HR 0.52 for death, 95% CI 0.3–0.9)<sup><a href="#ref-46">46</a></sup>. The importance of targeting adjuvant capecitabine to those with residual disease was recently highlighted by the results of the phase 3 GEICAM/CIBOMA trial. This randomised phase 3 trial of 876 patients who had early-stage TNBC and who had completed standard adjuvant or neoadjuvant polychemotherapy was designed to analyse the impact of adjuvant capecitabine (1000 mg/m<sup>2</sup> from days 1 to 14, every 21 days) for all patients with TNBC regardless of their pCR status. There was no significant difference in 5-year DFS and OS between the treatment groups, highlighting the need to choose a treatment-resistant group<sup><a href="#ref-47">47</a></sup>. The results of the CREATE-X trial now compel most clinicians to treat early-stage TNBC with neoadjuvant chemotherapy in order to understand who should have capecitabine. Whilst capecitabine should be considered, ongoing trials are evaluating new agents for TNBC with residual disease after neoadjuvant chemotherapy.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d8627e1151>Does immunotherapy (CTLA4 and PD-(L)1 inhibitors) improve pathological complete response?</h2><p class="" id=d8627e1154>The programmed cell death 1 (PD-1) inhibitors nivolumab and pembrolizumab and the programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab are monoclonal antibodies designed to release inhibition of the PD-1/PD-L1–mediated immune response, whereas ipilimumab releases inhibition of the cytotoxic T-lymphocyte-associated protein 4 (CTLA4)-mediated immune response. TNBC tumour cells use the PD-1/PD-L1 and CTLA4 immune pathways to avoid immune surveillance and proliferate but these monoclonal antibodies facilitate an effective immune-mediated and anti-tumour response<sup><a href="#ref-48">48</a></sup>.</p><p class="" id=d8627e1161>Pembrolizumab combined with anthracycline and taxane chemotherapy has pushed the pCR boundary even further. Impressive pCR rates of up to 90% have been reported in phase 1b and 2 clinical trials (<a href="#T3">Table 3</a>).</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Neoadjuvant clinical trials in triple-negative breast cancer using combinations of chemotherapy with or without immunotherapy.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d8627e1178 class=n-a></a><thead><a name=d8627e1180 class=n-a></a><tr><a name=d8627e1182 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e1184 class=n-a></a>Study</th><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e1187 class=n-a></a>Number of<br class=br>patients</th><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e1192 class=n-a></a>Trial arms</th><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e1195 class=n-a></a>pCR rate</th></tr></thead><tbody><a name=d8627e1200 class=n-a></a><tr><a name=d8627e1202 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1204 class=n-a></a>I-SPY 2<sup><a href="#ref-52">52</a></sup><br class=br>Phase 2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1212 class=n-a></a>69</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1215 class=n-a></a>T → AC<br class=br>T and pembro → AC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1220 class=n-a></a>Control: 22.3%<br class=br>Pembro: 62.4%</td></tr><tr><a name=d8627e1226 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1228 class=n-a></a>KEYNOTE-173<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup><br class=br>Phase 1b</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1239 class=n-a></a>20</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1242 class=n-a></a>A: pembro → pembro and nab-pac → pembro and AC.<br class=br>B: pembro → pembro and nab-pac 100 mg/m<sup>2</sup> and Cp (AUC 6) → pembro and AC<br class=br>C: pembro → pembro and nab-pac 125 mg/m<sup>2</sup> and Cp (AUC 5)→ pembro and AC<br class=br>D: pembro → pembro and nab-pac 125 mg/m<sup>2</sup> and Cp (AUC 2)→ pembro and AC<br class=br>E: pembro → pembro and T and Cp (AUC 5)→ pembro and AC<br class=br>F: pembro → pembro and T and Cp (AUC 2)→ pembro and AC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1265 class=n-a></a>A: 60%<br class=br>B: 90%<br class=br>Overall pCR rate<br class=br>(A–E): 60%</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d8627e1279 class=n-a></a><p id=d8627e1281> AC, doxorubicin and cyclophosphamide; AUC, area under curve; Cp, carboplatin; Nab-pac, nab-paclitaxel; pCR, pathological complete response; Pembro, pembrolizumab; T, paclitaxel.</p></div></div></div><p class="" id=d8627e1287>Patient selection for the optimal use of these agents is important and will likely be critical to their success in terms of DFS and OS outcomes, as seen in the CREATE-X and GEICAM-CIBOMA trials. The BCT 1702-CHARIOT clinical trial (ANZCTR N12617000651381) was designed to help guide clinicians in the management of patients with TNBC that is not responding to standard neoadjuvant therapy. The phase 2 clinical trial combines paclitaxel with ipilimumab and nivolumab in eligible patients with a residual TNBC of at least 15 mm and less than 50% reduction in longest diameter of the tumour after completion of four standard cycles of anthracycline chemotherapy. The trial is designed to select out the most at-risk TNBC population to see whether they can derive benefit from the novel combination of therapies as these patients have been reported to have pCR rates of less than 10% and hence the highest risk of dying from their disease<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>. Furthermore, selection and duration of these myriad adjuvant therapies will be important to delineate as the outcomes of ongoing clinical trials (<a href="#T4">Table 4</a>) are eagerly awaited.</p><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. Ongoing, unreported phase 3 clinical trials of (neo)adjuvant chemotherapy with or without immunotherapy.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d8627e1312 class=n-a></a><thead><a name=d8627e1314 class=n-a></a><tr><a name=d8627e1316 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e1318 class=n-a></a>Study</th><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e1321 class=n-a></a>Agents/Intervention</th><th align=left colspan=1 rowspan=1 valign=top><a name=d8627e1324 class=n-a></a>Outcome of interest</th></tr></thead><tbody><a name=d8627e1329 class=n-a></a><tr><a name=d8627e1331 class=n-a></a><td align=left colspan=3 rowspan=1 valign=top><a name=d8627e1333 class=n-a></a><b>Neoadjuvant studies</b></td></tr><tr><a name=d8627e1338 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1340 class=n-a></a>Impassion031<br class=br>NCT03197935</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1345 class=n-a></a>Atezolizumab<br class=br>Nab-paclitaxel<br class=br>Anthracyclines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1352 class=n-a></a>pCR<br class=br>EFS<br class=br>OS</td></tr><tr><a name=d8627e1360 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1362 class=n-a></a>NeoTRIPaPDL1<br class=br>NCT02620280</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1367 class=n-a></a>Atezolizumab<br class=br>Carboplatin<br class=br>Abraxane<br class=br>AC, EC or FEC </td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1376 class=n-a></a>EFS<br class=br>pCR</td></tr><tr><a name=d8627e1382 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1384 class=n-a></a>Keynote522<br class=br>NCT03036488</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1389 class=n-a></a>Pembrolizumab<br class=br>Paclitaxel, carboplatin<br class=br>Anthracycline</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1396 class=n-a></a>pCR<br class=br>EFS<br class=br>OS</td></tr><tr><a name=d8627e1404 class=n-a></a><td align=left colspan=3 rowspan=1 valign=top><a name=d8627e1406 class=n-a></a><b>Adjuvant studies</b></td></tr><tr><a name=d8627e1412 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1414 class=n-a></a>SWOG 1418<br class=br>NCT02954874</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1419 class=n-a></a>Pembrolizumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1422 class=n-a></a>iDFS<br class=br>OS<br class=br>dRFS</td></tr><tr><a name=d8627e1430 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1432 class=n-a></a>IMpassion030<br class=br>NCT03498716</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1437 class=n-a></a>Atezolizumab<br class=br>Paclitaxel<br class=br>ddAC or ddEC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1444 class=n-a></a>iDFS<br class=br>OS<br class=br>DFS<br class=br>RFI</td></tr><tr><a name=d8627e1454 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1456 class=n-a></a>A-Brave<br class=br>NCT02926196</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1461 class=n-a></a>Avelumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d8627e1464 class=n-a></a>DFS<br class=br>OS</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d8627e1474 class=n-a></a><p id=d8627e1476> AC, doxorubicin and cyclophosphamide; ddAC, dose dense doxorubicin and cyclophosphamide; ddEC, dose dense epirubicin and cyclophosphamide; DFS, disease-free survival; dRFS, disease recurrence-free survival; EC, epirubicin and cyclophosphamide; EFS, event-free survival; FEC, 5-fluorouracil and epirubicin and cyclophosphamide; iDFS, invasive disease-free survival; OS, overall survival; pCR, pathological complete response; RFI, recurrence-free interval.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d8627e1485>Systemic therapy for metastatic disease</h2><p class="" id=d8627e1488>Patients with metastatic TNBC experience poorer outcomes when compared with patients with other breast cancer subtypes<sup><a href="#ref-51">51</a></sup>. First-line systemic treatment typically includes a taxane or anthracycline combination<sup><a href="#ref-55">55</a></sup>, and median OS tends to be 18 months or less<sup><a href="#ref-56">56</a>–<a href="#ref-58">58</a></sup>. Novel treatment approaches are critical to improve these dire survival outcomes.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d8627e1510>Role of poly (ADP-ribose) polymerase inhibitors and chemotherapy for <i>BRCA</i>1 and <i>BRCA</i>2 mutation carriers</h2><p class="" id=d8627e1519>The OlympiAD clinical trial randomly assigned patients with advanced HER2-negative breast cancer and a germline <i>BRCA</i> mutation to a PARP inhibitor, olaparib (300 mg twice daily), or standard physician’s choice chemotherapy<sup><a href="#ref-59">59</a></sup>. The significant progression-free survival (PFS) benefit favoured olaparib with a median PFS of 7.2 months (versus 4.2 months)<sup><a href="#ref-59">59</a></sup>. Subgroup analysis of PFS for randomised stratification factors revealed an outstanding HR for progression of 0.39 (95% CI 0.27–0.57) amongst the TNBC subset, which made up nearly 50% of the treatment cohorts in both arms<sup><a href="#ref-59">59</a></sup>.</p><p class="" id=d8627e1537>The EMBRACA clinical trial compared the PARP inhibitor talazoparib (1 mg daily) with protocol-specified standard therapy (capecitabine, eribulin, gemcitabine or vinorelbine) and found a favourable median PFS of 8.6 versus 5.6 months in the standard therapy group (HR for progression or death 0.54, 95% CI 0.41–0.71) with a trend towards an OS benefit, but the data are immature<sup><a href="#ref-60">60</a></sup>. Although rates of adverse events were similar in the two treatment arms, patients randomly assigned to talazoparib reported superior quality-of-life outcomes (as recorded by the EORTC QLQ-C30) with a significant delay in the onset of a clinically meaningful deterioration in global health status<sup><a href="#ref-60">60</a></sup>.</p><p class="" id=d8627e1548>The results of the randomised phase 3 trials BRAVO (ClinicalTrials.gov Identifier: NCT01905592) using niraparib 300 mg daily<sup><a href="#ref-61">61</a></sup> versus chemotherapy and BROCADE (ClinicalTrials.gov Identifier: NCT02163694) using veliparib or placebo combined with chemotherapy in a similar cohort (germline <i>BRCA</i> mutation-positive) are still pending.</p><p class="" id=d8627e1558>The addition of iniparib to gemcitabine and carboplatin has shown promising results for all patients with metastatic TNBC regardless of their <i>BRCA</i> mutation status. A randomised phase 2 clinical trial showed that the addition of iniparib prolonged the median PFS from 3.6 to 5.9 months (HR for progression, 0.59; <i>P</i> = 0.01) and the median OS from 7.7 to 12.3 months (HR for death, 0.57; <i>P</i> = 0.01)<sup><a href="#ref-62">62</a></sup>. The phase 3 clinical trial did not meet the pre-specified co-primary end points, PFS and OS, but did report an efficacy signal for patients randomly assigned to second- or third-line PARP inhibitor therapy<sup><a href="#ref-62">62</a></sup>. This is likely because iniparib is no longer considered a true PARP inhibitor for the purposes of clinical research. Although iniparib inhibited PARP-1 function <i>in vitro</i> and was tested in clinical trials for this reason, subsequent studies have shown that the cell killing mechanism of iniparib does not reflect PARP inhibition<sup><a href="#ref-42">42</a>–<a href="#ref-44">44</a></sup>.</p><p class="" id=d8627e1590>Notably, the Triple-Negative Breast Cancer Trial (TNT) has provided important insights into the role of platinum- and taxane-based chemotherapy<sup><a href="#ref-63">63</a></sup>. The trial enrolled 376 patients with either a known deleterious <i>BRCA1/2</i> germline mutation (and any metastatic breast cancer phenotype) or metastatic TNBC. Although no significant difference was seen in the overall TNT population, a significantly better objective response rate of 68% to carboplatin versus 33% to docetaxel was found amongst the 43 patients with a germline <i>BRCA1/2</i> mutation<sup><a href="#ref-63">63</a></sup>. Furthermore, within this population, a PFS benefit favouring carboplatin (median PFS of 6.8 versus 4.4 months) was found without a corresponding OS benefit<sup><a href="#ref-63">63</a></sup>. Once again, the benefit was not reflected in the overall TNT population, where there was no significant PFS or OS advantage to either agent<sup><a href="#ref-63">63</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d8627e1619>IMpassion 130: Will immunotherapy be the winner for advanced triple-negative breast cancer too?</h2><p class="" id=d8627e1622>Prior to October 2018, phase 1 and 2 clinical trials evaluating PD-1 protein blockade as monotherapy in advanced TNBC showed disappointing response rates of 5 to 10% in unselected cohorts<sup><a href="#ref-64">64</a>–<a href="#ref-66">66</a></sup>. These poor response rates likely reflect that breast cancer is not a highly immunogenic solid organ malignancy<sup><a href="#ref-67">67</a></sup>. This has been thought to underlie the modest response rates seen with checkpoint inhibitor monotherapy to date; as a result, patients with advanced breast cancer need to be selected for the presence of pre-existing activity of the host immune system<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup>. The complexity of this response, when analysed in more detail, is apparent; however, tumour-infiltrating lymphocytes (TILs) simply measured by using light microscopy on hematoxylin-and-eosin–stained slides particularly have provided important insights into this variable response rate<sup><a href="#ref-70">70</a></sup>. TILs are mononuclear immune cells that infiltrate tumour tissue and are composed mainly of CD4<sup>+</sup> and CD8<sup>+</sup> (cytotoxic) T cells<sup><a href="#ref-71">71</a></sup>. TILs are an independent prognostic biomarker in breast cancer, and in early-stage, node-positive TNBC, high TILs correlatewith improved survival<sup><a href="#ref-72">72</a>,<a href="#ref-73">73</a></sup>. In addition to TILs, PD-1 and PD-L1 can be expressed by tumour cells and their presence can be evaluated as part of a detailed pathological examination of the tumour by using proprietary IHC assays<sup><a href="#ref-74">74</a>,<a href="#ref-75">75</a></sup>. In metastatic TNBC, better response rates were noted with pembrolizumab monotherapy in tumours with higher quantitative levels of TILs<sup><a href="#ref-76">76</a></sup>. Ultimately, it is highly likely that all of these immune markers read out a similar signal for selecting patients most likely to respond to PD-1 or PD-L1 inhibition or both.</p><p class="" id=d8627e1676>The recent approval of atezolizumab in advanced TNBC was based on the IMpassion 130 study. IMpassion 130 was a phase 3 registration study that randomly assigned over 900 patients with incurable TNBC who had relapsed 12 months or more after adjuvant chemotherapy to receive either nab-paclitaxel and atezolizumab (a PD-L1 inhibitor) or nab-paclitaxel and placebo. A statistically superior PFS benefit was seen: median PFS values of 7.2 months (95% CI 5.6–7.2 months) in the atezolizumab and taxane arm and 5.5 months (95% CI 5.3–5.6 months) with chemotherapy alone (HR = 0.8, 95% CI 0.69–0.92; <i>P</i> = 0.0025) were reported; among the PD-L1–positive tumours, median PFS values of 7.5 months (95% CI 6.7–9.2 months) and 5 months (95% CI 3.8–5.6 months) were reported (HR = 0.62, 95% CI 0.49–0.78; <i>P</i> &lt;0.0001); hence, the primary end point of the study was met<sup><a href="#ref-77">77</a></sup>. Interim OS analysis (60% of events) already showed a trend towards the atezolizumab and taxane combination with median OS values of 21.3 and 17.6 months (stratified HR 0.84, 95% CI 0.69–1.02)<sup><a href="#ref-77">77</a></sup>. Furthermore, 40% of the population did not receive any prior chemotherapy. It is likely that this group of patients with metastatic TNBC does much better both in general and with immunotherapy. Still, the first steps have been taken in the field, and we have much work to do to positively impact survival in this population.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d8627e1696>What can we expect next?</h2><p class="" id=d8627e1699>Recently, the treatment of both early and advanced TNBC has seen significant improvements in response rates and survival outcomes. The time has now come to stratify and personalise patient management according to response for early-stage disease and to the presence or absence of an immune infiltrate for advanced disease.</p><p class="" id=d8627e1702>Patients with early-stage disease who do not achieve pCR after neoadjuvant chemotherapy should be offered six to eight cycles of adjuvant capecitabine monotherapy, in accordance with the CREATE-X trial. For patients with advanced disease who are PD-L1<sup>+</sup>, CD8<sup>+</sup>, or TIL<sup>+</sup>, optimal treatment would include up-front atezolizumab and nab-paclitaxel. Exposure to a PD-1 or PD-L1 agent (or both) is likely still important for survival in patients who do not receive the combination in the first-line setting. Whether those who have a positive immune infiltrate and a disease-free interval of less than 12 months benefit from this regimen is unknown. Those without a positive immune infiltrate should be referred for a clinical trial that uses combinations of novel agents, chemotherapy and immunotherapy. The TNBC treatment landscape is an ever-evolving space, which epitomises the crucial relationship between laboratory and clinical research. The complex interplay has enabled practise-changing advances in treatment outcomes not seen in TNBC for decades.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d8627e1717>Abbreviations</h2><p class="" id=d8627e1720>BRCA, breast cancer gene; DFS, disease-free survival; OS, overall survival; PARP, poly (ADP-ribose) polymerase; pCR, pathological complete response; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; TIL, tumour-infiltrating lymphocyte; TNBC, triple-negative breast cancer</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d8627e1 class=n-a></a><h2 class=main-title id=d8890>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d8627e1727 class=n-a></a><h2 class=main-title id=d8627e1729>Acknowledgements</h2><p class="" id=d8627e1732>SL and AB are supported by the National Breast Cancer Foundation of Australia and the Breast Cancer Research Foundation (New York, NY, USA).</p></div><div class=back-section><a name=d8627e1736 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d9121>References</h2><div class="section ref-list"><a name=d8627e1736 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732889288"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e1743 class=n-a></a>Pareja F, Reis-Filho JS: Triple-negative breast cancers - a panoply of cancer types. <i>Nat Rev Clin Oncol.</i> 2018; <b>15</b>(6): 347–8. <a target=xrefwindow id=d8627e1751 href="http://www.ncbi.nlm.nih.gov/pubmed/29555966">PubMed Abstract </a> | <a target=xrefwindow id=d8627e1754 href="https://doi.org/10.1038/s41571-018-0001-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732889288">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/6107956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e1767 class=n-a></a>Hammond ME, Hayes DF, Dowsett M, <i> et al.</i>: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. <i>J Clin Oncol.</i> 2010; <b>28</b>(16): 2784–95. <a target=xrefwindow id=d8627e1778 href="http://www.ncbi.nlm.nih.gov/pubmed/20404251">PubMed Abstract </a> | <a target=xrefwindow id=d8627e1781 href="https://doi.org/10.1200/JCO.2009.25.6529">Publisher Full Text </a> | <a target=xrefwindow id=d8627e1785 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2881855">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/6107956">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733321759"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e1798 class=n-a></a>Wolff AC, Hammond MEH, Allison KH, <i> et al.</i>: Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>J Clin Oncol.</i> 2018; <b>36</b>(20): 2105–22. <a target=xrefwindow id=d8627e1809 href="http://www.ncbi.nlm.nih.gov/pubmed/29846122">PubMed Abstract </a> | <a target=xrefwindow id=d8627e1812 href="https://doi.org/10.1200/JCO.2018.77.8738">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733321759">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d8627e1825 class=n-a></a>Foulkes WD, Smith IE, Reis-Filho JS: Triple-negative breast cancer. <i>N Engl J Med.</i> 2010; <b>363</b>(20): 1938–48. <a target=xrefwindow id=d8627e1833 href="http://www.ncbi.nlm.nih.gov/pubmed/21067385">PubMed Abstract </a> | <a target=xrefwindow id=d8627e1836 href="https://doi.org/10.1056/NEJMra1001389">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d8627e1845 class=n-a></a>Haffty BG, Yang Q, Reiss M, <i> et al.</i>: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. <i>J Clin Oncol.</i> 2006; <b>24</b>(36): 5652–7. <a target=xrefwindow id=d8627e1856 href="http://www.ncbi.nlm.nih.gov/pubmed/17116942">PubMed Abstract </a> | <a target=xrefwindow id=d8627e1859 href="https://doi.org/10.1200/JCO.2006.06.5664">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d8627e1869 class=n-a></a>Liedtke C, Mazouni C, Hess KR, <i> et al.</i>: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. <i>J Clin Oncol.</i> 2008; <b>26</b>(8): 1275–81. <a target=xrefwindow id=d8627e1880 href="http://www.ncbi.nlm.nih.gov/pubmed/18250347">PubMed Abstract </a> | <a target=xrefwindow id=d8627e1883 href="https://doi.org/10.1200/JCO.2007.14.4147">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d8627e1892 class=n-a></a>von Minckwitz G, Untch M, Blohmer JU, <i> et al.</i>: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. <i>J Clin Oncol.</i> 2012; <b>30</b>(15): 1796–804. <a target=xrefwindow id=d8627e1903 href="http://www.ncbi.nlm.nih.gov/pubmed/22508812">PubMed Abstract </a> | <a target=xrefwindow id=d8627e1906 href="https://doi.org/10.1200/JCO.2011.38.8595">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d8627e1915 class=n-a></a>Cortazar P, Zhang L, Untch M, <i> et al.</i>: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet.</i> 2014; <b>384</b>(9938): 164–72. <a target=xrefwindow id=d8627e1926 href="http://www.ncbi.nlm.nih.gov/pubmed/24529560">PubMed Abstract </a> | <a target=xrefwindow id=d8627e1929 href="https://doi.org/10.1016/S0140-6736(13)62422-8">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d8627e1938 class=n-a></a>Spring LM, Fell G, Arfe A, <i> et al.</i>: Abstract GS2-03: Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients. <i>Cancer Res.</i> 2019; <b>79</b>(4 Supplement): GS2–03. <a target=xrefwindow id=d8627e1949 href="https://doi.org/10.1158/1538-7445.SABCS18-GS2-03">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d8627e1958 class=n-a></a>Le Tourneau C, Dettwiler S, Laurence V, <i> et al.</i>: 47% pathologic complete response rate to anthracyclines based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients. <i>Breast Cancer Res Treat.</i> 2007; <b>106</b>(1): abstract 4010. </span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d8627e1976 class=n-a></a>Bidard FC, Matthieu MC, Chollet P, <i> et al.</i>: p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. <i>Ann Oncol.</i> 2008; <b>19</b>(7): 1261–5. <a target=xrefwindow id=d8627e1987 href="https://doi.org/10.1093/annonc/mdn039">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d8627e1997 class=n-a></a>Fernandez-Morales LA, Dalmau E, Martinez S, <i> et al.</i>: Analysis of the pathological response to primary chemotherapy in patients with locally advanced breast cancer (LABC) grouped according to ER, PR and HER2 status. <i>J Clin Oncol.</i> 2006; <b>24</b>(18_suppl): 626–6. <a target=xrefwindow id=d8627e2008 href="https://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.626">Reference Source</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d8627e2017 class=n-a></a>Carey LA, Dees EC, Sawyer L, <i> et al.</i>: The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. <i>Clin Cancer Res.</i> 2007; <b>13</b>(8): 2329–34. <a target=xrefwindow id=d8627e2028 href="http://www.ncbi.nlm.nih.gov/pubmed/17438091">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2031 href="https://doi.org/10.1158/1078-0432.CCR-06-1109">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d8627e2040 class=n-a></a>Keam B, Im SA, Kim HJ, <i> et al.</i>: Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. <i>BMC Cancer.</i> 2007; <b>7</b>: 203. <a target=xrefwindow id=d8627e2051 href="http://www.ncbi.nlm.nih.gov/pubmed/17976237">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2054 href="https://doi.org/10.1186/1471-2407-7-203">Publisher Full Text </a> | <a target=xrefwindow id=d8627e2058 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2217558">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d8627e2067 class=n-a></a>Esserman LJ, Perou C, Cheang M, <i> et al.</i>: Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). <i>JCO.</i> 2009; <b>27</b>: LBA515–LBA515. <a target=xrefwindow id=d8627e2078 href="https://doi.org/10.1200/jco.2009.27.18_suppl.lba515">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d8627e2087 class=n-a></a>Wang S, Yang H, Tong F, <i> et al.</i>: Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. <i>Gan To Kagaku Ryoho.</i> 2009; <b>36</b>(2): 255–8. <a target=xrefwindow id=d8627e2098 href="http://www.ncbi.nlm.nih.gov/pubmed/19223741">PubMed Abstract </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d8627e2107 class=n-a></a>Straver ME, Glas AM, Hannemann J, <i> et al.</i>: The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Res Treat.</i> 2010; <b>119</b>(3): 551–8. <a target=xrefwindow id=d8627e2118 href="http://www.ncbi.nlm.nih.gov/pubmed/19214742">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2121 href="https://doi.org/10.1007/s10549-009-0333-1">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d8627e2131 class=n-a></a>Huober J, von Minckwitz G, Denkert C, <i> et al.</i>: Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. <i>Breast Cancer Res Treat.</i> 2010; <b>124</b>(1): 133–40. <a target=xrefwindow id=d8627e2142 href="http://www.ncbi.nlm.nih.gov/pubmed/20697801">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2145 href="https://doi.org/10.1007/s10549-010-1103-9">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d8627e2154 class=n-a></a>Rouzier R: Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. <i>Clin Cancer Res.</i> 2005; <b>11</b>(16): 5678–85. <a target=xrefwindow id=d8627e2162 href="http://www.ncbi.nlm.nih.gov/pubmed/16115903">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2165 href="https://doi.org/10.1158/1078-0432.CCR-04-2421">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d8627e2174 class=n-a></a>Garber JE, Richardson A, Harris LN, <i> et al.</i>: Neo-adjuvant cisplatin (CDDP) in “triple-negative” breast cancer (BC). <i>Breast Cancer Res Treat.</i> 2006; <b>100</b>(1): abstract 3074. </span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d8627e2192 class=n-a></a>Sikov WM, Fenton MA, Strenger R, <i> et al.</i>: Preliminary recurrence and survival analysis of patients (pts) receiving neoadjuvant q4week carboplatin and weekly paclitaxel þ weekly trastuzumab in resectable and locally advanced breast cancer: update of BrUOG BR-95. <i>Breast Cancer Res Treat.</i> 2007; <b>106</b>: abstract 506. </span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d8627e2210 class=n-a></a>Torrisi R, Balduzzi A, Ghisini R, <i> et al.</i>: Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. <i>Cancer Chemother Pharmacol.</i> 2008; <b>62</b>(4): 667–72. <a target=xrefwindow id=d8627e2221 href="http://www.ncbi.nlm.nih.gov/pubmed/18064460">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2224 href="https://doi.org/10.1007/s00280-007-0652-z">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d8627e2233 class=n-a></a>Leone JP, Guardiola V, Venkatraman A, <i> et al.</i>: Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): Retrospective analysis of 125 patients. <i>J Clin Oncol.</i> 2009; <b>27</b>(15_suppl): 625–5. <a target=xrefwindow id=d8627e2244 href="https://www.semanticscholar.org/paper/Neoadjuvant-platinum-based-chemotherapy-(CT)-for-of-Leone-Guardiola/113bb49e03f9a28ad56bf249796e6c499672a391">Reference Source</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d8627e2254 class=n-a></a>Byrski T, Huzarski T, Dent R, <i> et al.</i>: Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. <i>Breast Cancer Res Treat.</i> 2009; <b>115</b>(2): 359–63. <a target=xrefwindow id=d8627e2265 href="http://www.ncbi.nlm.nih.gov/pubmed/18649131">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2268 href="https://doi.org/10.1007/s10549-008-0128-9">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732796213"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e2277 class=n-a></a>Loibl S, O'Shaughnessy J, Untch M, <i> et al.</i>: Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): A randomised, phase 3 trial. <i>Lancet Oncol.</i> 2018; <b>19</b>(4): 497–509. <a target=xrefwindow id=d8627e2288 href="http://www.ncbi.nlm.nih.gov/pubmed/29501363">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2291 href="https://doi.org/10.1016/S1470-2045(18)30111-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732796213">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736215357"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e2304 class=n-a></a>Litton JK, Scoggins M, Hess KR, <i> et al.</i>: Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). <i>JCO.</i> 2018; <b>36</b>(15_suppl): 508. <a target=xrefwindow id=d8627e2315 href="https://doi.org/10.1200/JCO.2018.36.15_suppl.508">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736215357">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d8627e2328 class=n-a></a>Untch M, Jackisch C, Schneeweiss A, <i> et al.</i>: Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): A randomised, phase 3 trial. <i>Lancet Oncol.</i> 2016; <b>17</b>: 345–56. <a target=xrefwindow id=d8627e2339 href="http://www.ncbi.nlm.nih.gov/pubmed/26869049">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2342 href="https://doi.org/10.1016/S1470-2045(15)00542-2">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735746845"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e2351 class=n-a></a>Gianni L, Mansutti M, Anton A, <i> et al.</i>: Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. <i>JAMA Oncol.</i> 2018; <b>4</b>(3): 302–8. <a target=xrefwindow id=d8627e2362 href="http://www.ncbi.nlm.nih.gov/pubmed/29327055">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2365 href="https://doi.org/10.1001/jamaoncol.2017.4612">Publisher Full Text </a> | <a target=xrefwindow id=d8627e2369 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5885830">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735746845">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d8627e2382 class=n-a></a>Gluz O, Nitz U, Liedtke C, <i> et al.</i>: Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. <i>J Natl Cancer Inst.</i> 2018; <b>110</b>(6): 628–637. <a target=xrefwindow id=d8627e2393 href="http://www.ncbi.nlm.nih.gov/pubmed/29228315">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2396 href="https://doi.org/10.1093/jnci/djx258">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d8627e2406 class=n-a></a>Zhang P, Yin Y, Mo H, <i> et al.</i>: Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: A randomized phase 2 trial. <i>Oncotarget.</i> 2016; <b>7</b>(37): 60647–56. <a target=xrefwindow id=d8627e2417 href="http://www.ncbi.nlm.nih.gov/pubmed/27447966">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2420 href="https://doi.org/10.18632/oncotarget.10607">Publisher Full Text </a> | <a target=xrefwindow id=d8627e2424 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5312408">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d8627e2433 class=n-a></a>Alba E, Chacon JI, Lluch A, <i> et al.</i>: A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. <i>Breast Cancer Res Treat.</i> 2012; <b>136</b>(2): 487–93. <a target=xrefwindow id=d8627e2444 href="http://www.ncbi.nlm.nih.gov/pubmed/23053638">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2447 href="https://doi.org/10.1007/s10549-012-2100-y">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d8627e2456 class=n-a></a>Silver DP, Richardson AL, Eklund AC, <i> et al.</i>: Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. <i>J Clin Oncol.</i> 2010; <b>28</b>(7): 1145–53. <a target=xrefwindow id=d8627e2467 href="http://www.ncbi.nlm.nih.gov/pubmed/20100965">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2470 href="https://doi.org/10.1200/JCO.2009.22.4725">Publisher Full Text </a> | <a target=xrefwindow id=d8627e2474 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2834466">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730353760"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e2483 class=n-a></a>Werner TL, Ray A, Lamb JG, <i> et al.</i>: A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. <i>Clin Breast Cancer.</i> 2017; <b>17</b>(7): 503–9. <a target=xrefwindow id=d8627e2494 href="http://www.ncbi.nlm.nih.gov/pubmed/28579139">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2497 href="https://doi.org/10.1016/j.clbc.2017.04.010">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730353760">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d8627e2510 class=n-a></a>Telli ML, Jensen KC, Vinayak S, <i> et al.</i>: Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and <i>BRCA1/2</i> Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. <i>JCO.</i> 2015; <b>33</b>(17): 1895–901. <a target=xrefwindow id=d8627e2524 href="http://www.ncbi.nlm.nih.gov/pubmed/25847929">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2528 href="https://doi.org/10.1200/JCO.2014.57.0085">Publisher Full Text </a> | <a target=xrefwindow id=d8627e2531 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4451172">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718520595"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e2540 class=n-a></a>Sikov WM, Berry DA, Perou CM, <i> et al.</i>: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). <i>J Clin Oncol.</i> 2015; <b>33</b>(1): 13–21. <a target=xrefwindow id=d8627e2551 href="http://www.ncbi.nlm.nih.gov/pubmed/25092775">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2554 href="https://doi.org/10.1200/JCO.2014.57.0572">Publisher Full Text </a> | <a target=xrefwindow id=d8627e2558 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4268249">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718520595">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727381025"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e2572 class=n-a></a>Jovanović B, Mayer IA, Mayer EL, <i> et al.</i>: A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. <i>Clin Cancer Res.</i> 2017; <b>23</b>(15): 4035–45. <a target=xrefwindow id=d8627e2583 href="http://www.ncbi.nlm.nih.gov/pubmed/28270498">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2586 href="https://doi.org/10.1158/1078-0432.CCR-16-3055">Publisher Full Text </a> | <a target=xrefwindow id=d8627e2590 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5540799">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727381025">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d8627e2603 class=n-a></a>Nabholtz JM, Chalabi N, Radosevic-Robin N, <i> et al.</i>: Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer. <i>Int J Cancer.</i> 2016; <b>138</b>(9): 2274–80. <a target=xrefwindow id=d8627e2614 href="http://www.ncbi.nlm.nih.gov/pubmed/26649807">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2617 href="https://doi.org/10.1002/ijc.29952">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d8627e2626 class=n-a></a>Gerber B, Loibl S, Eidtmann H, <i> et al.</i>: Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). <i>Ann Oncol.</i> 2013; <b>24</b>(12): 2978–84. <a target=xrefwindow id=d8627e2637 href="http://www.ncbi.nlm.nih.gov/pubmed/24136883">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2640 href="https://doi.org/10.1093/annonc/mdt361">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d8627e2649 class=n-a></a>Nabholtz JM, Abrial C, Mouret-Reynier MA, <i> et al.</i>: Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. <i>Ann Oncol.</i> 2014; <b>25</b>(8): 1570–7. <a target=xrefwindow id=d8627e2660 href="http://www.ncbi.nlm.nih.gov/pubmed/24827135">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2663 href="https://doi.org/10.1093/annonc/mdu183">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718373634"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e2672 class=n-a></a>von Minckwitz G, Schneeweiss A, Loibl S, <i> et al.</i>: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. <i>Lancet Oncol.</i> 2014; <b>15</b>(7): 747–56. <a target=xrefwindow id=d8627e2683 href="http://www.ncbi.nlm.nih.gov/pubmed/24794243">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2686 href="https://doi.org/10.1016/S1470-2045(14)70160-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718373634">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d8627e2699 class=n-a></a>Telli ML, Timms KM, Reid J, <i> et al.</i>: Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. <i>Clin Cancer Res.</i> 2016; <b>22</b>(15): 3764–73. <a target=xrefwindow id=d8627e2710 href="http://www.ncbi.nlm.nih.gov/pubmed/26957554">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2713 href="https://doi.org/10.1158/1078-0432.CCR-15-2477">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d8627e2723 class=n-a></a>Liu X, Shi Y, Maag DX, <i> et al.</i>: Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. <i>Clin Cancer Res.</i> 2012; <b>18</b>(2): 510–23. <a target=xrefwindow id=d8627e2734 href="http://www.ncbi.nlm.nih.gov/pubmed/22128301">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2737 href="https://doi.org/10.1158/1078-0432.CCR-11-1973">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d8627e2746 class=n-a></a>Patel AG, De Lorenzo SB, Flatten KS, <i> et al.</i>: Failure of iniparib to inhibit poly(ADP-Ribose) polymerase <i>in vitro</i>. <i>Clin Cancer Res.</i> 2012; <b>18</b>(6): 1655–62. <a target=xrefwindow id=d8627e2760 href="http://www.ncbi.nlm.nih.gov/pubmed/22291137">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2764 href="https://doi.org/10.1158/1078-0432.CCR-11-2890">Publisher Full Text </a> | <a target=xrefwindow id=d8627e2767 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3306513">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d8627e2776 class=n-a></a>Pierce A, McGowan PM, Cotter M, <i> et al.</i>: Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. <i>Cancer Biol Ther.</i> 2013; <b>14</b>(6): 537–45. <a target=xrefwindow id=d8627e2787 href="http://www.ncbi.nlm.nih.gov/pubmed/23760496">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2790 href="https://doi.org/10.4161/cbt.24349">Publisher Full Text </a> | <a target=xrefwindow id=d8627e2794 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3813570">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732540149"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e2803 class=n-a></a>Tutt A: Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness. <i>Ann Oncol.</i> 2018; <b>29</b>(1): 18–21. <a target=xrefwindow id=d8627e2811 href="http://www.ncbi.nlm.nih.gov/pubmed/29300815">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2814 href="https://doi.org/10.1093/annonc/mdx775">Publisher Full Text </a> | <a target=xrefwindow id=d8627e2817 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5834033">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732540149">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727674364"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e2830 class=n-a></a>Masuda N, Lee SJ, Ohtani S, <i> et al.</i>: Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. <i>N Engl J Med.</i> 2017; <b>376</b>(22): 2147–59. <a target=xrefwindow id=d8627e2841 href="https://doi.org/10.1056/NEJMoa1612645">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727674364">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d8627e2854 class=n-a></a>Martín M, Barrios CH, Torrecillas L, <i> et al.</i>: Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. <i>Cancer Res.</i> 2019; Feb 15; <b>79</b>(4 Supplement): GS2–04. <a target=xrefwindow id=d8627e2865 href="https://doi.org/10.1158/1538-7445.SABCS18-GS2-04">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d8627e2875 class=n-a></a>Chen DS, Mellman I: Oncology Meets Immunology: The Cancer-Immunity Cycle. <i>Immunity.</i> 2013; <b>39</b>(1): 1–10. <a target=xrefwindow id=d8627e2883 href="http://www.ncbi.nlm.nih.gov/pubmed/23890059">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2886 href="https://doi.org/10.1016/j.immuni.2013.07.012">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d8627e2895 class=n-a></a>von Minckwitz G, Kümmel S, Vogel P, <i> et al.</i>: Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. <i>J Natl Cancer Inst.</i> 2008; <b>100</b>(8): 552–62. <a target=xrefwindow id=d8627e2906 href="http://www.ncbi.nlm.nih.gov/pubmed/18398094">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2909 href="https://doi.org/10.1093/jnci/djn089">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d8627e2918 class=n-a></a>von Minckwitz G, Blohmer JU, Costa SD, <i> et al.</i>: Response-guided neoadjuvant chemotherapy for breast cancer. <i>J Clin Oncol.</i> 2013; <b>31</b>(29): 3623–30. <a target=xrefwindow id=d8627e2929 href="http://www.ncbi.nlm.nih.gov/pubmed/24002511">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2932 href="https://doi.org/10.1200/JCO.2012.45.0940">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d8627e2941 class=n-a></a>den Brok WD, Speers CH, Gondara L, <i> et al.</i>: Survival with metastatic breast cancer based on initial presentation, <i>de novo</i> versus relapsed. <i>Breast Cancer Res Treat.</i> 2017; <b>161</b>(3): 549–56. <a target=xrefwindow id=d8627e2955 href="http://www.ncbi.nlm.nih.gov/pubmed/28000014">PubMed Abstract </a> | <a target=xrefwindow id=d8627e2959 href="https://doi.org/10.1007/s10549-016-4080-9">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735113056"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e2968 class=n-a></a>Nanda R, Liu MC, Yau C, <i> et al.</i>: Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. <i>JCO.</i> 2017; <b>35</b>: 506. <a target=xrefwindow id=d8627e2979 href="https://doi.org/10.1200/JCO.2017.35.15_suppl.506">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735113056">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735243688"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e2992 class=n-a></a>Schmid P, Park YH, Muñoz-Couselo E, <i> et al.</i>: Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. <i>JCO.</i> 2017; <b>35</b>: 556. <a target=xrefwindow id=d8627e3003 href="https://doi.org/10.1200/JCO.2017.35.15_suppl.556">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735243688">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d8627e3017 class=n-a></a>Schmid P, Park YH, Muñoz-Couselo E, <i> et al.</i>: Abstract PD5-01: KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC). <i>Cancer Res.</i> 2019; <b>79</b>(4 Supplement): PD5–01. <a target=xrefwindow id=d8627e3028 href="https://doi.org/10.1158/1538-7445.SABCS18-PD5-01">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d8627e3037 class=n-a></a>Cardoso F, Senkus E, Costa A, <i> et al.</i>: 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. <i>Ann Oncol.</i> 2018; <b>29</b>(8): 1634–57. <a target=xrefwindow id=d8627e3048 href="http://www.ncbi.nlm.nih.gov/pubmed/30032243">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3051 href="https://doi.org/10.1093/annonc/mdy192">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733058465"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e3060 class=n-a></a>Gobbini E, Ezzalfani M, Dieras V, <i> et al.</i>: Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. <i>Eur J Cancer.</i> 2018; <b>96</b>: 17–24. <a target=xrefwindow id=d8627e3071 href="http://www.ncbi.nlm.nih.gov/pubmed/29660596">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3074 href="https://doi.org/10.1016/j.ejca.2018.03.015">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733058465">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733400528"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e3087 class=n-a></a>Yardley DA, Coleman R, Conte P, <i> et al.</i>: <i>nab</i>-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. <i>Ann Oncol.</i> 2018; <b>29</b>(8): 1763–70. <a target=xrefwindow id=d8627e3101 href="http://www.ncbi.nlm.nih.gov/pubmed/29878040">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3105 href="https://doi.org/10.1093/annonc/mdy201">Publisher Full Text </a> | <a target=xrefwindow id=d8627e3108 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6096741">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733400528">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d8627e3121 class=n-a></a>Miles DW, Diéras V, Cortés J, <i> et al.</i>: First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. <i>Ann Oncol.</i> 2013; <b>24</b>(11): 2773–80. <a target=xrefwindow id=d8627e3132 href="http://www.ncbi.nlm.nih.gov/pubmed/23894038">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3135 href="https://doi.org/10.1093/annonc/mdt276">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727687763"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e3144 class=n-a></a>Robson M, Im SA, Senkus E, <i> et al.</i>: Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation. <i>N Engl J Med.</i> 2017; <b>377</b>(6): 523–33. <a target=xrefwindow id=d8627e3158 href="http://www.ncbi.nlm.nih.gov/pubmed/28578601">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3162 href="https://doi.org/10.1056/NEJMoa1706450">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727687763">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733817864"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e3176 class=n-a></a>Litton JK, Rugo HS, Ettl J, <i> et al.</i>: Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation. <i>N Engl J Med.</i> 2018; <b>379</b>(8): 753–63. <a target=xrefwindow id=d8627e3190 href="http://www.ncbi.nlm.nih.gov/pubmed/30110579">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3194 href="https://doi.org/10.1056/NEJMoa1802905">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733817864">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d8627e3207 class=n-a></a>Sandhu SK, Schelman WR, Wilding G, <i> et al.</i>: The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in <i>BRCA</i> mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. <i>Lancet Oncol.</i> 2013; <b>14</b>(9): 882–92. <a target=xrefwindow id=d8627e3221 href="http://www.ncbi.nlm.nih.gov/pubmed/23810788">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3225 href="https://doi.org/10.1016/S1470-2045(13)70240-7">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/8186975"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e3234 class=n-a></a>O'Shaughnessy J, Osborne C, Pippen JE, <i> et al.</i>: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. <i>N Engl J Med.</i> 2011; <b>364</b>(3): 205–14. <a target=xrefwindow id=d8627e3245 href="http://www.ncbi.nlm.nih.gov/pubmed/21208101">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3248 href="https://doi.org/10.1056/NEJMoa1011418">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/8186975">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733152797"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e3261 class=n-a></a>Tutt A, Tovey H, Cheang MCU, <i> et al.</i>: Carboplatin in <i>BRCA1/2</i>-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. <i>Nat Med.</i> 2018; <b>24</b>(5): 628–37. <a target=xrefwindow id=d8627e3275 href="http://www.ncbi.nlm.nih.gov/pubmed/29713086">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3279 href="https://doi.org/10.1038/s41591-018-0009-7">Publisher Full Text </a> | <a target=xrefwindow id=d8627e3282 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6372067">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733152797">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732029486"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e3295 class=n-a></a>Dirix LY, Takacs I, Jerusalem G, <i> et al.</i>: Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. <i>Breast Cancer Res Treat.</i> 2018; <b>167</b>(3): 671–86. <a target=xrefwindow id=d8627e3306 href="http://www.ncbi.nlm.nih.gov/pubmed/29063313">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3309 href="https://doi.org/10.1007/s10549-017-4537-5">Publisher Full Text </a> | <a target=xrefwindow id=d8627e3313 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5807460">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732029486">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d8627e3326 class=n-a></a>Adams S, Schmid P, Rugo HS, <i> et al.</i>: Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. <i>JCO.</i> 2017; <b>35</b>: 1008. <a target=xrefwindow id=d8627e3337 href="https://doi.org/10.1200/JCO.2017.35.15_suppl.1008">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734027977"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e3347 class=n-a></a>Emens LA, Cruz C, Eder JP, <i> et al.</i>: Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. <i>JAMA Oncol.</i> 2019; <b>5</b>(1): 74–82. <a target=xrefwindow id=d8627e3358 href="http://www.ncbi.nlm.nih.gov/pubmed/30242306">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3361 href="https://doi.org/10.1001/jamaoncol.2018.4224">Publisher Full Text </a> | <a target=xrefwindow id=d8627e3365 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6439773">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734027977">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d8627e3378 class=n-a></a>Martincorena I, Campbell PJ: Somatic mutation in cancer and normal cells. <i>Science.</i> 2015; <b>349</b>(6255): 1483–9. <a target=xrefwindow id=d8627e3386 href="http://www.ncbi.nlm.nih.gov/pubmed/26404825">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3389 href="https://doi.org/10.1126/science.aab4082">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734230835"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e3398 class=n-a></a>Adams S, Loi S, Toppmeyer D, <i> et al.</i>: Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. <i>JCO.</i> 2017; <b>35</b>(15_suppl): 1088. <a target=xrefwindow id=d8627e3409 href="https://doi.org/10.1200/JCO.2017.35.15_suppl.1088">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734230835">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d8627e3422 class=n-a></a>Schmid P, Cruz C, Braiteh FS, <i> et al.</i>: Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. <i>Cancer Res.</i> 2017; <b>77</b>(13 Supplement): 2986. <a target=xrefwindow id=d8627e3433 href="https://doi.org/10.1158/1538-7445.AM2017-2986">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d8627e3442 class=n-a></a>Salgado R, Denkert C, Demaria S, <i> et al.</i>: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. <i>Ann Oncol.</i> 2015; <b>26</b>(2): 259–71. <a target=xrefwindow id=d8627e3453 href="http://www.ncbi.nlm.nih.gov/pubmed/25214542">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3456 href="https://doi.org/10.1093/annonc/mdu450">Publisher Full Text </a> | <a target=xrefwindow id=d8627e3460 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6267863">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d8627e3469 class=n-a></a>Ruffell B, Au A, Rugo HS, <i> et al.</i>: Leukocyte composition of human breast cancer. <i>Proc Natl Acad Sci U S A.</i> 2012; <b>109</b>(8): 2796–801. <a target=xrefwindow id=d8627e3480 href="http://www.ncbi.nlm.nih.gov/pubmed/21825174">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3483 href="https://doi.org/10.1073/pnas.1104303108">Publisher Full Text </a> | <a target=xrefwindow id=d8627e3487 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3287000">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717976513"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e3497 class=n-a></a>Loi S, Sirtaine N, Piette F, <i> et al.</i>: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. <i>JCO.</i> 2013; <b>31</b>(7): 860–7. <a target=xrefwindow id=d8627e3508 href="http://www.ncbi.nlm.nih.gov/pubmed/23341518">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3511 href="https://doi.org/10.1200/JCO.2011.41.0902">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717976513">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d8627e3524 class=n-a></a>Loi S, Michiels S, Salgado R, <i> et al.</i>: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. <i>Ann Oncol.</i> 2014; <b>25</b>(8): 1544–50. <a target=xrefwindow id=d8627e3535 href="http://www.ncbi.nlm.nih.gov/pubmed/24608200">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3538 href="https://doi.org/10.1093/annonc/mdu112">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d8627e3547 class=n-a></a>Gatalica Z, Snyder C, Maney T, <i> et al.</i>: Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. <i>Cancer Epidemiol Biomarkers Prev.</i> 2014; <b>23</b>(12): 2965–70. <a target=xrefwindow id=d8627e3558 href="http://www.ncbi.nlm.nih.gov/pubmed/25392179">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3561 href="https://doi.org/10.1158/1055-9965.EPI-14-0654">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d8627e3570 class=n-a></a>Patel SP, Kurzrock R: PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. <i>Mol Cancer Ther.</i> 2015; <b>14</b>(4): 847–56. <a target=xrefwindow id=d8627e3578 href="http://www.ncbi.nlm.nih.gov/pubmed/25695955">PubMed Abstract </a> | <a target=xrefwindow id=d8627e3581 href="https://doi.org/10.1158/1535-7163.MCT-14-0983">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d8627e3590 class=n-a></a>Loi S, Adams S, Schmid P, <i> et al.</i>: LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. <i>Ann Oncol.</i> 2017; <b>28</b>. <a target=xrefwindow id=d8627e3601 href="https://doi.org/10.1093/annonc/mdx440.005">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734257085"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d8627e3610 class=n-a></a>Schmid P, Adams S, Rugo HS, <i> et al.</i>: Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>N Engl J Med.</i> 2018; <b>379</b>: 2108–21. <a target=xrefwindow id=d8627e3621 href="https://doi.org/10.1056/NEJMoa1809615">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734257085">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 02 Aug 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1342&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1342&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia<br/> <sup>2</sup> Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia<br/> <p> <div class=margin-bottom> Alice R T Bergin <br/> <span>Roles: </span> Investigation, Methodology, Writing – Original Draft Preparation </div> <div class=margin-bottom> Sherene Loi <br/> <span>Roles: </span> Supervision, Validation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1342/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 02 Aug 2019, 8:1342 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.18888.1">https://doi.org/10.12688/f1000research.18888.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Bergin ART and Loi S. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=20701 data-id=18888 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18888.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1342/v1/pdf?article_uuid=12dc649f-058a-4275-9036-eded4cbc270a" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.18888.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Bergin ART and Loi S. Triple-negative breast cancer: recent treatment advances [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1342 (<a href="https://doi.org/10.12688/f1000research.18888.1" target=_blank>https://doi.org/10.12688/f1000research.18888.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=18888 id=mobile-track-article-signin-18888 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18888?target=/articles/8-1342"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20701 /> <input name=articleId type=hidden value=18888 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Kazuaki Takabe</strong>, Division of Breast Surgery, Department of Surgical Oncology, Roswell Park Cancer Institute, USA; Department of Surgery, Jacobs School of Medicine and Biomedical Sciences, The State University of New York Buffalo, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Heather L. McArthur</strong>, Cedars-Sinai Medical Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Heather McArthur has previously consulted or had an advisory role for Merck, Spectrum Pharmaceuticals, Lilly, Amgen, Immunomedics, Pfizer, Genentech, Bristol-Meyers Squibb and Genomic Health. Additionally, Heather was on the expert panel for Lilly in 2017. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 02 Aug 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1342&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1342&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=50851-52025></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=54312-52030></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1342/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>02 Aug 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Kazuaki Takabe</strong>, Division of Breast Surgery, Department of Surgical Oncology, Roswell Park Cancer Institute, USA; Department of Surgery, Jacobs School of Medicine and Biomedical Sciences, The State University of New York Buffalo, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Heather L. McArthur</strong>, Cedars-Sinai Medical Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Heather McArthur has previously consulted or had an advisory role for Merck, Spectrum Pharmaceuticals, Lilly, Amgen, Immunomedics, Pfizer, Genentech, Bristol-Meyers Squibb and Genomic Health. Additionally, Heather was on the expert panel for Lilly in 2017. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1342&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1342/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Triple-negative breast cancer: recent treatment...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1342/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1342/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1342/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Bergin ART and Loi S');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1342/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1342",
            templates : {
                twitter : "Triple-negative breast cancer: recent treatment advances. Bergin ART and Loi S, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1342/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Triple-negative breast cancer: recent treatment advances", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Triple-negative breast cancer: recent treatment advances", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/18888/20701")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "20701");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "52025": 0,
                           "52030": 3,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "2e4878c9-a50b-4b4a-a0f0-98a23bbfe142";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1342.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1342.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1342.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1342.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1342.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>